Literature DB >> 8364209

Effects of agents that inhibit cellular iron incorporation on bladder cancer cell proliferation.

P A Seligman1, R B Schleicher, G Siriwardana, J Domenico, E W Gelfand.   

Abstract

Agents that interfere with cellular iron (Fe) incorporation inhibit tumor cell proliferation, including metals that bind to transferrin (Tf) such as gallium (Ga) or indium (In) and Fe chelators such as desferrioxamine (DFO). Ga nitrate is effective in the treatment of metastatic bladder cancer and these patients exhibit evidence for interference with Fe metabolism. We show here that bladder cancer cell proliferation in vitro is dependent on Tf-Fe. Concentrations of DFO that can be readily achieved in vivo inhibit cellular proliferation even in the presence of physiologic concentrations of Tf-Fe. Inhibition of proliferation by Tf-Ga is associated with decreased cellular Fe incorporation. However, when a physiologic concentration of Tf-Fe is added to an equimolar concentration of Tf-Ga, significant Fe incorporation is evident despite inhibition of proliferation. Thus, besides interference with Fe incorporation, Ga may also interfere with intracellular Fe distribution and/or directly inhibit an Fe- (or non-Fe-) requiring process necessary for cellular proliferation. DFO followed sequentially by Tf-Ga results in marked potentiation of inhibition of proliferation. The effects of this combination appear to be related to both interference with Fe metabolism and increased Ga uptake. This sequential combination may be useful in the treatment of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364209

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Modulation of iron on mitochondrial aconitase expression in human prostatic carcinoma cells.

Authors:  Horng-Heng Juang
Journal:  Mol Cell Biochem       Date:  2004-10       Impact factor: 3.396

2.  Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities.

Authors:  D R Richardson
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 3.  Pharmacology of iron transport.

Authors:  Shaina L Byrne; Divya Krishnamurthy; Marianne Wessling-Resnick
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-09-27       Impact factor: 13.820

4.  Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator.

Authors:  Shaoyu Wang; Vincent J Higgins; Janice R Aldrich-Wright; Ming J Wu
Journal:  J Chem Biol       Date:  2011-12-06

Review 5.  Desferoxamine (DFO)--mediated iron chelation: rationale for a novel approach to therapy for brain cancer.

Authors:  Pouya N Dayani; Maria C Bishop; Keith Black; Paul M Zeltzer
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

6.  5‑Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis.

Authors:  Yasushi Nakai; Yoshihiro Tatsumi; Shunta Hori; Yosuke Morizawa; Kota Iida; Kenta Onishi; Makito Miyake; Yuki Oda; Takuya Owari; Tomomi Fujii; Sayuri Onishi; Nobumichi Tanaka; Kiyohide Fujimoto
Journal:  Oncol Rep       Date:  2022-09-09       Impact factor: 4.136

7.  Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo.

Authors:  Shaina L Byrne; Peter D Buckett; Jonghan Kim; Flora Luo; Jack Sanford; Juxing Chen; Caroline Enns; Marianne Wessling-Resnick
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

8.  Mitochondrial ferritin, a new target for inhibiting neuronal tumor cell proliferation.

Authors:  Zhen-Hua Shi; Fang-Fang Shi; Yue-Qi Wang; Alex D Sheftel; Guangjun Nie; Ya-Shuo Zhao; Lin-Hao You; Yu-Jing Gou; Xiang-Lin Duan; Bao-Lu Zhao; Hong-Meng Xu; Chun-Yan Li; Yan-Zhong Chang
Journal:  Cell Mol Life Sci       Date:  2014-09-12       Impact factor: 9.261

9.  Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.

Authors:  Kana Komoto; Takahiro Nomoto; Sjaikhurrizal El Muttaqien; Hiroyasu Takemoto; Makoto Matsui; Yutaka Miura; Nobuhiro Nishiyama
Journal:  Cancer Sci       Date:  2020-11-29       Impact factor: 6.518

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.